Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition

about

Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition

Item

http://www.wikidata.org/entity/Q41083899

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Histone deacetylase 3 overexpr ...... rowth via apoptosis inhibition

@en

type

Item

label

Histone deacetylase 3 overexpr ...... rowth via apoptosis inhibition

@en

prefLabel

Histone deacetylase 3 overexpr ...... rowth via apoptosis inhibition

@en

P1476

Histone deacetylase 3 overexpr ...... rowth via apoptosis inhibition

@en

P2093

Mingming Zhang

http://www.w3.org/2001/XMLSchema#string

Qian Zhou

http://www.w3.org/2001/XMLSchema#string

Robert Gregory Dorfman

http://www.w3.org/2001/XMLSchema#string

Shan Huang

http://www.w3.org/2001/XMLSchema#string

Shimin Zhao

http://www.w3.org/2001/XMLSchema#string

Xiaoping Zou

http://www.w3.org/2001/XMLSchema#string

Yang Li

http://www.w3.org/2001/XMLSchema#string

Yida Pan

http://www.w3.org/2001/XMLSchema#string

Yuling Yao

http://www.w3.org/2001/XMLSchema#string

Yuyao Yin

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4.

HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

Epigenetic therapy of cancer with histone deacetylase inhibitors

New and emerging HDAC inhibitors for cancer treatment

Histone deacetylase inhibitors in cancer treatment

Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family

The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

High-precision radiosurgical dose delivery by interlaced microbeam arrays of high-flux low-energy synchrotron X-rays.

P304

e2856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CDDIS.2016.457

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28569784

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

5520875

http://www.w3.org/2001/XMLSchema#string